GalNAc vs Lipid Conjugation

How this supports a project

GalNAc and lipid conjugates do not provide interchangeable targeting labels. GalNAc architecture is commonly designed for ASGPR-mediated hepatocyte uptake, while lipid conjugation changes hydrophobicity and association with proteins or lipoprotein pathways in a structure- and scaffold-dependent manner.

Start with the biological route, not the ligand name

Multivalent GalNAc conjugates are used to engage the asialoglycoprotein receptor on hepatocytes. Valency, spatial presentation, attachment position, linker, oligonucleotide format, and chemical modification pattern can affect receptor binding, uptake, intracellular processing, and RNA activity. A GalNAc label alone does not define the complete conjugate.

Lipid conjugation can alter oligonucleotide hydrophobicity, plasma-protein or lipoprotein association, tissue distribution, cellular uptake, and clearance. Cholesterol, fatty acids, sterols, vitamins, and phospholipid-like conjugates are not one delivery class with one behavior. Lipid structure, linker, attachment position, oligonucleotide scaffold, route, and dose context all matter.

What changes the decision

Targeting or distribution mechanism

For GalNAc, define ASGPR-positive hepatocyte targeting and receptor-relevant model. For a lipid conjugate, define the proposed protein, lipoprotein, membrane, depot, or local-delivery interaction and how it will be tested.

Ligand architecture

Specify GalNAc valency and presentation or the exact lipid class, chain, saturation, headgroup, stereochemistry, and hydrophobicity. Family names are insufficient.

Oligonucleotide scaffold

Record strand format, sequence, length, sugar and backbone modifications, terminal chemistry, duplex state, and stability. Delivery behavior cannot be separated from the oligonucleotide design.

Attachment and linker

Define strand, 3′ or 5′ position or internal site, linker length and composition, orientation, cleavable or stable bond, conjugation method, and expected metabolites.

Manufacture and analysis

Plan conjugation conversion, purification of unconjugated and partially conjugated species, identity, ligand loading or valency, sequence integrity, duplexing, free ligand, isomers, and stability.

Distribution and functional evidence

Measure intact conjugate and relevant metabolites, tissue and cell-type distribution, uptake, intracellular availability, target engagement or knockdown, duration, and matched unconjugated and ligand controls.

Information needed for selection

Biological objective

Target tissue and cell type, receptor or transport hypothesis, route, dose basis, required duration, model relevance, and evidence threshold.

Oligonucleotide definition

Sequence, strand format, length, sugar and backbone modifications, terminal groups, salt, duplex or single strand, amount, and analytical state.

Ligand and linker

Exact GalNAc architecture or lipid structure, valency where applicable, attachment site, linker, bond, protection state, conjugation handle, and release hypothesis.

Process and specification

Conjugation route, purification, identity, purity, unconjugated oligo, free ligand, ligand loading, isomers, residuals, counterions, water, formulation, and storage.

Study controls

Unconjugated oligo, non-targeting sequence, ligand-free or alternate-ligand comparator, receptor or pathway control, matched dose and chemistry, distribution assay, and functional readout.

Limits of this comparison

CHEMOS can evaluate selected GalNAc ligands, lipid or cholesterol handles, linkers, functionalized supports, and cold nonclinical conjugation building blocks. This comparison does not establish tissue targeting, receptor specificity, biodistribution, cellular uptake, endosomal escape, knockdown, potency, duration, safety, clinical suitability, freedom to operate, or regulatory status. Those conclusions require the exact finished oligonucleotide conjugate and an appropriate study.

FAQ

Can the same oligo use either route?

A sequence can be used in separate GalNAc and lipid-conjugate studies, but the scaffold, linker, attachment, purification, dose, controls, and biological evaluation must be defined for each finished conjugate.

What product information matters first?

Define the biological route, complete oligonucleotide modification map, exact ligand or lipid, attachment site, linker, conjugation method, specification, and study controls.

Related catalog and technical pages

Oligo conjugation and delivery ligandsBrowse GalNAc ligands, lipid and cholesterol handles, click handles, and oligo-conjugation linkers.Oligonucleotide modification chemistryReview sequence maps, backbone and sugar modifications, terminal handles, conjugation planning, and final-strand analysis.Oligonucleotide programsReview how sequence, modification map, synthesis inputs, conjugation, purification, and final analysis are assembled.Conjugation chemistry and linkersReview attachment sites, spacer function, reaction order, purification, and final-conjugate controls.Oligonucleotide synthesisReview solid-phase inputs, terminal handles, deprotection, strand purification, conjugation, and finished-material analysis.